NovoCure's Cash from Operations rose 9828.45% to $20.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.5 million, marking a year-over-year increase of 799.98%. This contributed to the annual value of -$26.4 million for FY2024, which is 6404.36% up from last year.
According to the latest figures from Q3 2025, NovoCure's Cash from Operations is $20.6 million, which was up 9828.45% from -$15.9 million recorded in Q2 2025.
In the past 5 years, NovoCure's Cash from Operations ranged from a high of $26.2 million in Q2 2021 and a low of -$35.7 million during Q1 2025
Moreover, its 5-year median value for Cash from Operations was -$3.5 million (2024), whereas its average is -$904631.6.
In the last 5 years, NovoCure's Cash from Operations skyrocketed by 80853.35% in 2021 and then crashed by 82651.16% in 2025.
Quarter analysis of 5 years shows NovoCure's Cash from Operations stood at $14.4 million in 2021, then plummeted by 125.74% to -$3.7 million in 2022, then plummeted by 292.72% to -$14.6 million in 2023, then skyrocketed by 76.29% to -$3.5 million in 2024, then surged by 696.18% to $20.6 million in 2025.
Its last three reported values are $20.6 million in Q3 2025, -$15.9 million for Q2 2025, and -$35.7 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value